Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02137837 · ClinicalTrials.gov registry record · Phase 3
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 3
- Development phase
- 37
- Enrollment target
NCT02137837 is a Phase 3 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 37 participants.
The verdict
NCT02137837, a Phase 3 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 37 participants
- Enrollment target
Study Summary
This randomized Phase III trial studies how well the combination of fulvestrant and everolimus together or the combination of anastrozole, fulvestrant and everolimus together, improve progression-free survival (PFS) versus fulvestrant alone.
Interventions
- DRUG Anastrozole
- DRUG Everolimus
- DRUG Fulvestrant
- DRUG Placebo - Anastrozole
- DRUG Placebo - Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2014-05 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02137837
The ClinicalTrials.gov registry entry for NCT02137837 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Anastrozole is the first listed.
NCT02137837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02137837 about?
NCT02137837 is a clinical study titled "S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer". This randomized Phase III trial studies how well the combination of fulvestrant and everolimus together or the combination of anastrozole, fulvestrant and everolimus together, improve progression-free survival (PFS) versus fulvestrant alone.
What is the current status of trial NCT02137837?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 37 participants. The study started on 2014-05. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT02137837?
The interventions under investigation include: Anastrozole (DRUG), Everolimus (DRUG), Fulvestrant (DRUG), Placebo - Anastrozole (DRUG), Placebo - Everolimus (DRUG).
Who is sponsoring clinical trial NCT02137837?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.